… therapy compared with long-acting β-agonist/long-acting muscarinic antagonist … long-acting
bronchodilator in patients with stable COPD who complained of dyspnea and/or exercise …

… with improvements in dyspnea and exercise performance. We … that TLC is almost constant
when corrected for age, there is a … bronchodilator in patients with COPD improved the IC and …

… increase exercise tolerance during high intensity, constant work rate, cycle ergometer exercise
in stable COPD patients … bronchodilator therapies in COPD: a network meta-analysis. Int J …

… Long-acting bronchodilators and inhaled corticosteroids (… We also examined functional
capacity (timed walking tests and … –Sidik–Jonkman variance correction was used as a sensitivity …

… of patients, included different long-acting pharmacological … long-acting bronchodilators
(LABDs), either long-acting muscarinic antagonist or long-acting beta adrenergic bronchodilators…

… dyspnea and increased exercise performance. Citation23,… In this study, short-acting
bronchodilators, long-acting beta2 … included studies have reported this correction. The need to …

… many patients who are receiving long-acting bronchodilators … therapy is to improve exercise
capacity in COPD patients, dual … This meta-analysis also suggested a greater ability of dual …

… , out-of-pocket costs for patients, and exercise capacity were ranked as important outcomes.
… , dual long-acting bronchodilator therapy is more expensive than long-acting bronchodilator …

… This systematic literature review and network meta-analysis (NMA) … Long-acting bronchodilators
are the mainstay of … relevant to patients with COPD, such as exercise capacity, because …

… and exercise tolerance … COPD patients with persistent symptoms or history of exacerbations
should be treated with combined long-acting muscarinic antagonists (LAMA) and long-acting …